MicroRNA-195 inhibits the behavior of cervical cancer tumors by directly targeting HDGF

Song,Rongrong; Cong,Lin; Ni,Guantai; Chen,Min; Sun,Honmei; Sun,Yunxia; Chen,Meiling

doi:10.3892/ol.2017.6210

MicroRNA-195 inhibits the behavior of cervical cancer tumors by directly targeting HDGF

Authors:
- Rongrong Song
- Lin Cong
- Guantai Ni
- Min Chen
- Honmei Sun
- Yunxia Sun
- Meiling Chen
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China, Department of Obstetrics and Gynecology, The People's Hospital of Xuancheng, Xuancheng, Anhui 242000, P.R. China
Published online on: May 19, 2017 https://doi.org/10.3892/ol.2017.6210
Pages: 767-775
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) are a class of conserved non‑coding endogenous small regulatory RNAs that regulate target gene expression by binding to the 3'‑untranslated region of target mRNAs in a base‑pairing manner, resulting in repression of transcription or degradation of target mRNAs. It has been demonstrated previously that the abnormal expression of miRNAs is involved in the carcinogenesis and progression of cervical cancer. The aim of the present study was to investigate the expression, biological functions and underlying molecular mechanisms of miR‑195 in cervical cancer. The reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to detect the expression level of miR‑195 in cervical cancer tissues and cell lines. Following transfection, an MTT assay, cell migration and invasion assays, western blot analysis and a dual‑luciferase reporter assay were performed in human cervical cancer cells. In the present study, it was identified that miR‑195 was downregulated in cervical cancer tissues and cell lines. Additionally, upregulation of miR‑195 and knockdown of hepatoma‑derived growth factor (HDGF) inhibited proliferation, migration and invasion of cervical cancer cells. Furthermore, a dual‑luciferase reporter assay identified that HDGF was a direct target gene of miR‑195. RT‑qPCR and western blot analysis demonstrated that miR‑195 mimic inhibited HDGF expression at the mRNA and protein levels, whereas miR‑195 inhibitor enhanced HDGF expression at the mRNA and protein levels. These results indicated that miR‑195 targeted HDGF to inhibit the behavior of tumors in cervical cancer. These results also suggested that miR‑195 was a potential therapeutic biomarker of cervical cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
4	Xiao S, Liao S, Zhou Y, Jiang B, Li Y and Xue M: High expression of octamer transcription factor 1 in cervical cancer. Oncol Lett. 7:1889–1894. 2014.PubMed/NCBI
5	Zhang J, Jia J, Zhao L, Li X, Xie Q, Chen X, Wang J and Lu F: Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell. Mol Carcinog. 55:732–742. 2016. View Article : Google Scholar : PubMed/NCBI
6	Bosch FX, Lorincz A, Munoz N, Meijer CJ and Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 55:244–265. 2002. View Article : Google Scholar : PubMed/NCBI
7	Yee GP, de Souza P and Khachigian LM: Current and potential treatments for cervical cancer. Curr Cancer Drug Targets. 13:205–220. 2013. View Article : Google Scholar : PubMed/NCBI
8	Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M and Williams CJ: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet. 358:781–786. 2001. View Article : Google Scholar : PubMed/NCBI
9	Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL III, Walker JL and Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 340:1154–1161. 1999. View Article : Google Scholar : PubMed/NCBI
10	Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
11	Mayr NA, Huang Z, Wang JZ, Lo SS, Fan JM, Grecula JC, Sammet S, Sammet CL, Jia G, Zhang J, et al: Characterizing tumor heterogeneity with functional imaging and quantifying high-risk tumor volume for early prediction of treatment outcome: Cervical cancer as a model. Int J Radiat Oncol Biol Phys. 83:972–979. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kogo R, How C, Chaudary N, Bruce J, Shi W, Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar : PubMed/NCBI
13	Song X, Shi B, Huang K and Zhang W: miR-133a inhibits cervical cancer growth by targeting EGFR. Oncol Rep. 34:1573–1580. 2015.PubMed/NCBI
14	Chen Y, Ma C, Zhang W, Chen Z and Ma L: Down regulation of miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical squamous cancer. Diagn Pathol. 9:882014. View Article : Google Scholar : PubMed/NCBI
15	Liu L, Wang YL and Wang JF: Differential expression of miR-21, miR-126, miR-143, miR-373 in normal cervical tissue, cervical cancer tissue and Hela cell. Sichuan Da Xue Xue Bao Yi Xue Ban. 43:536–539. 2012.(In Chinese). PubMed/NCBI
16	Moreno-Moya JM, Vilella F and Simón C: MicroRNA: Key gene expression regulators. Fertil Steril. 101:1516–1523. 2014. View Article : Google Scholar : PubMed/NCBI
17	Vasudevan S, Tong Y and Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science. 318:1931–1934. 2007. View Article : Google Scholar : PubMed/NCBI
18	Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T: Identification of novel genes coding for small expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
19	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
20	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
21	Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 96 Suppl:R40–R44. 2007.PubMed/NCBI
22	Fan W, Huang J, Xiao H and Liang Z: MicroRNA-22 is downregulated in clear cell renal cell carcinoma, and inhibits cell growth, migration and invasion by targeting PTEN. Mol Med Rep. 13:4800–4806. 2016.PubMed/NCBI
23	Shi C and Zhang Z: MicroRNA-362 is downregulated in cervical cancer and inhibits cell proliferation, migration and invasion by directly targeting SIX1. Oncol Rep. 37:501–509. 2017.PubMed/NCBI
24	Zhang S, Zhao Y and Wang L: MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1. Biochem Biophys Res Commun. 472:557–565. 2016. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Flavin RJ, Smyth PC, Laios A, O'Toole SA, Barrett C, Finn SP, Russell S, Ring M, Denning KM, Li J, et al: Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod Pathol. 22:197–205. 2009. View Article : Google Scholar : PubMed/NCBI
27	Zhu J, Ye Q, Chang L, Xiong W, He Q and Li W: Upregulation of miR-195 enhances the radiosensitivity of breast cancer cells through the inhibition of BCL-2. Int J Clin Exp Med. 8:9142–9148. 2015.PubMed/NCBI
28	Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
29	Liu B, Qu J, Xu F, Guo Y, Wang Y, Yu H and Qian B: MiR-195 suppresses non-small cell lung cancer by targeting CHEK1. Oncotarget. 6:9445–9456. 2015. View Article : Google Scholar : PubMed/NCBI
30	Sun N, Ye L, Chang T and Li X and Li X: microRNA-195-Cdc42 axis acts as a prognostic factor of esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 7:6871–6879. 2014.PubMed/NCBI
31	Yang Y, Li M, Chang S, Wang L, Song T, Gao L, Hu L, Li Z, Liu L, Yao J and Huang C: MicroRNA-195 acts as a tumor suppressor by directly targeting Wnt3a in HepG2 hepatocellular carcinoma cells. Mol Med Rep. 10:2643–2648. 2014.PubMed/NCBI
32	Jia LF, Wei SB, Gong K, Gan YH and Yu GY: Prognostic implications of micoRNA miR-195 expression in human tongue squamous cell carcinoma. PLoS One. 8:e566342013. View Article : Google Scholar : PubMed/NCBI
33	Luo Q, Wei C, Li X, Li J, Chen L, Huang Y, Song H, Li D and Fang L: MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. Oncol Rep. 31:1096–1102. 2014.PubMed/NCBI
34	Yang G, Wu D, Zhu J, Jiang O, Shi Q, Tian J and Weng Y: Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol Rep. 30:877–889. 2013.PubMed/NCBI
35	Guo H, Li W, Zheng T and Liu Z: MiR-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells. Tumour Biol. 35:8861–8866. 2014. View Article : Google Scholar : PubMed/NCBI
36	Wang X, Wang Y, Lan H and Li J: MiR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R. Tumour Biol. 35:8765–8770. 2014. View Article : Google Scholar : PubMed/NCBI
37	Huang JS, Chao CC, Su TL, Yeh SH, Chen DS, Chen CT, Chen PJ and Jou YS: Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 315:950–958. 2004. View Article : Google Scholar : PubMed/NCBI
38	Bao C, Wang J, Ma W, Wang X and Cheng Y: HDGF: A novel jack-of-all-trades in cancer. Future Oncol. 10:2675–2685. 2014. View Article : Google Scholar : PubMed/NCBI
39	Zhang J, Ren H, Yuan P, Lang W, Zhang L and Mao L: Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res. 66:18–23. 2006. View Article : Google Scholar : PubMed/NCBI
40	Ren H, Chu Z and Mao L: Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. 8:1106–1112. 2009. View Article : Google Scholar : PubMed/NCBI
41	Lee KH, Choi EY, Kim MK, Lee SH, Jang BI, Kim TN, Kim SW, Kim SW, Song SK, Kim JR and Jung BC: Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells. Oncol Res. 19:67–76. 2010. View Article : Google Scholar : PubMed/NCBI
42	Li SZ, Zhao YB, Cao WD, Qu Y, Luo P, Zhen HN, Chen XY, Yan ZF and Fei Z: The expression of hepatoma-derived growth factor in primary central nervous system lymphoma and its correlation with angiogenesis, proliferation and clinical outcome. Med Oncol. 30:6222013. View Article : Google Scholar : PubMed/NCBI
43	Ke Y, Zhao W, Xiong J and Cao R: Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett. 587:3153–3157. 2013. View Article : Google Scholar : PubMed/NCBI
44	Zhou Y, Zhou N, Fang W and Huo J: Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol. 5:582010. View Article : Google Scholar : PubMed/NCBI
45	Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, Enomoto H, Okuda Y, Sakon M, Aozasa K, et al: Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res. 12:6043–6048. 2006. View Article : Google Scholar : PubMed/NCBI
46	Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, Ito H, Hoshida Y, Aozasa K, Nagano H, et al: Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol. 13:159–167. 2006. View Article : Google Scholar : PubMed/NCBI
47	Tsai CC, Huang SC, Tai MH, Chien CC, Huang CC and Hsu YC: Hepatoma-derived growth factor upregulation is correlated with prognostic factors of early-stage cervical adenocarcinoma. Int J Mol Sci. 15:21492–21504. 2014. View Article : Google Scholar : PubMed/NCBI
48	Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA, Wang B, Lu MY, Pan CK and Chen P: Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. Biochem Biophys Res Commun. 435:466–471. 2013. View Article : Google Scholar : PubMed/NCBI
49	Chen B, Huang T, Jiang J, Lv L, Li H and Xia S: miR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF. Mol Cell Biochem. 388:211–218. 2014. View Article : Google Scholar : PubMed/NCBI